Work

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis

Year: 2018

Type: article

Source: Quality of Life Research

DOI: 10.1007/s11136-018-1984-3

Authors: David F. McDermott, Ruchit Shah, Komal Gupte-Singh, Javier Sabater, Linlin Luo, Marc Botteman, Sumati Rao, Meredith M. Regan, Michael Atkins

Institutions: Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, Pharmerit (United States), Bristol-Myers Squibb (United States), Servier (France), Dana-Farber Cancer Institute, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Bristol-Myers Squibb, European Society for Medical Oncology

OpenAlex ID: W2889854070

FWCI: 0.938

Cites: 38

Cited by: 17

Related to: 10